Smith-Magenis syndrome (SMS0) is a complex and rare genetic multisystem disorder characterized by a variable pattern of cognitive deficits accompanied by a1 distinctive behavioral phenotype. SMS is characterized by subtle facial dysmorphology, short stature, sleep disturbances, and neurobehavioral abnormalities. Little is known about the manifestation of his unique case among Arab population an...

The pharmacokinetics of alprazolam (ALP) after i.v. and p.o. administration in rats were characterized. ALP decayed biexponentially after the i.v. dose (1.25 mg/kg), but the concentration-time profiles after the p.o. doses (7 and 12.5 mg/kg) exhibited a doublepeak phenomenon. The presence of two peaks was confirmed by statistical analysis of the serum concentration data of ALP, as well as by ob...

The pharmacokinetics of alprazolam (ALP) after i.v. and p.o. administration in rats were characterized. ALP decayed biexponentially after the i.v. dose (1.25 mg/kg), but the concentration-time profiles after the p.o. doses (7 and 12.5 mg/kg) exhibited a doublepeak phenomenon. The presence of two peaks was confirmed by statistical analysis of the serum concentration data of ALP, as well as by ob...

The pharmacokinetics of alprazolam (ALP) after i.v. and p.o. administration in rats were characterized. ALP decayed biexponentially after the i.v. dose (1.25 mg/kg), but the concentration-time profiles after the p.o. doses (7 and 12.5 mg/kg) exhibited a doublepeak phenomenon. The presence of two peaks was confirmed by statistical analysis of the serum concentration data of ALP, as well as by ob...

The pharmacokinetics of alprazolam (ALP) after i.v. and p.o. administration in rats were characterized. ALP decayed biexponentially after the i.v. dose (1.25 mg/kg), but the concentration-time profiles after the p.o. doses (7 and 12.5 mg/kg) exhibited a doublepeak phenomenon. The presence of two peaks was confirmed by statistical analysis of the serum concentration data of ALP, as well as by ob...

The pharmacokinetics of alprazolam (ALP) after i.v. and p.o. administration in rats were characterized. ALP decayed biexponentially after the i.v. dose (1.25 mg/kg), but the concentration-time profiles after the p.o. doses (7 and 12.5 mg/kg) exhibited a doublepeak phenomenon. The presence of two peaks was confirmed by statistical analysis of the serum concentration data of ALP, as well as by ob...

The present study was designed to examine the specificity of (3-adrenergic antagonists for al-, 192-adrenergic and 5HT1B-serotonergic receptors by the compe titive interaction with 1251-iodocyanopindolol (1251-ICYP) as a radioligand. The 81 -adrenoceptors were preferred by acebutolol, atenolol, betaxolol, practolol, and I-, dl and d-metoprolol, while butoxamine and ICI-118,551 preferred 82-adre...

The pharmacokinetics of alprazolam (ALP) after i.v. and p.o. administration in rats were characterized. ALP decayed biexponentially after the i.v. dose (1.25 mg/kg), but the concentration-time profiles after the p.o. doses (7 and 12.5 mg/kg) exhibited a doublepeak phenomenon. The presence of two peaks was confirmed by statistical analysis of the serum concentration data of ALP, as well as by ob...

The pharmacokinetics of alprazolam (ALP) after i.v. and p.o. administration in rats were characterized. ALP decayed biexponentially after the i.v. dose (1.25 mg/kg), but the concentration-time profiles after the p.o. doses (7 and 12.5 mg/kg) exhibited a doublepeak phenomenon. The presence of two peaks was confirmed by statistical analysis of the serum concentration data of ALP, as well as by ob...